We have tried to position Guilford so that our partnering stems from strategic opportunity, not financial need. We seek partners who share our commitment to ‘speed, quality and results’ and our mission to ‘make a difference by making new medicines’. We seek partners who share our values of clear thinking, resourcefulness, adaptability, nimbleness, perseverance, ‘feel’ for clinical practice and patient needs, constant communication, consistent commitment and the will to make our own luck.

Thomas Seoh,
SVP Corporate Development, General Counsel and Secretary


Orion Pharma
Daiichi Radioisotope Laboratories (DRL)
MAP





Orion Pharma - for the Scandinavian marketing of GLIADEL® Wafer (polifeprosan 20 with carmustine implant). Orion received exclusive marketing, sales, and distribution rights to GLIADEL® Wafer in Finland, Sweden, Norway, and Denmark. Guilford manufactures and supplies GLIADEL® Wafer to Orion. Guilford received an up-front payment, and receives transfer payments on product sales to Orion.
Orion Pharma web site





Daiichi Radioisotope Laboratories (DRL) - for the development and marketing of DOPASCAN® Injection in parts of Asia. DRL received exclusive marketing, sales, and distribution rights to DOPASCAN® Injection in Japan, Korea, and Taiwan. Guilford is responsible for manufacturing and supplying the DOPASCAN® Injection precursor to DRL. DRL will radiolabel the precursor to make the final DOPASCAN® Injection product. Guilford received an up-front payment, and will receive milestone payments and royalties on product sales.
Daiichi Radioisotope Laboratories (DRL) web site


MAP Medical Technologies - for the development, marketing, sales and distribution rights to DOPASCAN® Injection for all European Union Member States and other select markets. MAP is responsible for seeking regulatory approvals, and for manufacturing, marketing and selling DOPASCAN® Injection in these countries. Guilford received an upfront payment and will receive milestone payments, and royalties on future product sales of DOPASCAN® Injection within MAP's territories.
MAP Medical Technologies web site



This page was last updated on Friday, April 16, 2004

Copyright© 2002 Guilford Pharmaceuticals Inc.
Legal Information